"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Descriptor ID |
D010190
|
MeSH Number(s) |
C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421
|
Concept/Terms |
Pancreatic Neoplasms- Pancreatic Neoplasms
- Neoplasm, Pancreatic
- Pancreatic Neoplasm
- Pancreas Neoplasms
- Neoplasm, Pancreas
- Neoplasms, Pancreas
- Pancreas Neoplasm
- Neoplasms, Pancreatic
Cancer of Pancreas- Cancer of Pancreas
- Pancreas Cancers
- Pancreas Cancer
- Cancer, Pancreas
- Cancers, Pancreas
- Pancreatic Cancer
- Cancer, Pancreatic
- Cancers, Pancreatic
- Pancreatic Cancers
- Cancer of the Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".
This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 4 | 1 | 5 |
1994 | 7 | 1 | 8 |
1995 | 13 | 3 | 16 |
1996 | 12 | 5 | 17 |
1997 | 14 | 2 | 16 |
1998 | 24 | 5 | 29 |
1999 | 16 | 3 | 19 |
2000 | 14 | 4 | 18 |
2001 | 31 | 1 | 32 |
2002 | 28 | 3 | 31 |
2003 | 62 | 6 | 68 |
2004 | 51 | 4 | 55 |
2005 | 86 | 6 | 92 |
2006 | 71 | 5 | 76 |
2007 | 89 | 10 | 99 |
2008 | 89 | 11 | 100 |
2009 | 96 | 11 | 107 |
2010 | 99 | 12 | 111 |
2011 | 111 | 14 | 125 |
2012 | 117 | 7 | 124 |
2013 | 98 | 10 | 108 |
2014 | 104 | 5 | 109 |
2015 | 104 | 6 | 110 |
2016 | 105 | 9 | 114 |
2017 | 105 | 6 | 111 |
2018 | 96 | 13 | 109 |
2019 | 105 | 7 | 112 |
2020 | 109 | 5 | 114 |
2021 | 94 | 3 | 97 |
2022 | 96 | 0 | 96 |
2023 | 55 | 0 | 55 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
ASO Visual Abstact: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023 Oct; 30(11):6569-6570.
-
ASO Visual Abstract: Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Non-metastatic Pancreatic Adenocarcinoma. Ann Surg Oncol. 2023 Oct; 30(11):6671-6672.
-
A blood-based metabolomic signature predictive of risk for pancreatic cancer. Cell Rep Med. 2023 09 19; 4(9):101194.
-
Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Oncotarget. 2023 Sep 15; 14:811-818.
-
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst. 2023 Sep 07; 115(9):1001-1010.
-
Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res. 2023 09 01; 29(17):3408-3417.
-
KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T?cells. Cancer Cell. 2023 09 11; 41(9):1606-1620.e8.
-
Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T?cells. Dev Cell. 2023 Sep 11; 58(17):1562-1577.e8.
-
Senescence program and its reprogramming in pancreatic premalignancy. Cell Death Dis. 2023 08 17; 14(8):528.
-
Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study. Breast Cancer Res Treat. 2023 Nov; 202(1):23-32.